Completed OBSERVATIONAL NCT00734591

Follow-Up Study for Exubera (FUSE)

An Observational Follow-Up Study Of Patients Previously Enrolled In Exubera Controlled Clinical Trials

Sponsor: Pfizer

Interventions Exubera Randomized diabetes therapy

Updated 9 times since 2017 Last updated: Sep 24, 2012 Started: Aug 31, 2008 Primary completion: Jan 31, 2012 Completion: Jan 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00734591, this observational or N/A phase trial focuses on Diabetes Mellitus and remains completed. Sponsored by Pfizer, it has been updated 9 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Completed
Sep 2024 — Sep 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Dec 2021 — Jul 2024 [monthly]

Completed
Jan 2021 — Dec 2021 [monthly]

Completed

▶ Show 4 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed
Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None
Feb 2017 — Apr 2018 [monthly]

Completed NA
Jan 2017 — Feb 2017 [monthly]

Completed NA

First recorded

Aug 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

's-Hertogenbosch, Netherlands , Aarhus, Denmark , Albany, United States , Albuquerque, United States , Altenburg, Germany , Alzira, Spain , Amiens, France , Amsterdam, Netherlands , Ann Arbor, United States , Armentières, France and 271 more locations